News & Events

• November 7, 2023
  

  C-Path’s T1D Consortium New-onset Article Published in The Lancet Diabetes and Endocrinology

  Research confirms immune-based therapies improve outcomes in new-onset T1D TUCSON, Ariz., November 7, 2023 — Critical Path Institute’s (C-Path) Type 1 Diabetes Consortium, along with external collaborators from Cardiff University and the University of Alberta, today announced the publishing of “C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes”...
• July 18, 2023
  

  C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships

  C-Path ts activity in Europe and broaden its global operations. C-Path operates in Europe as a nonprofit organisation that builds consensus among its stakeholders from around the world to improve public health. The organisation shares expertise, data, risks and costs to move regulatory science forward.

• September 27, 2022
  

  Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation

  C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.

• September 8, 2022
  

  C-Path’s Kristen Swingle Named President

  Swingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path...
• December 16, 2020
  

  C-Path and Diamyd Medical Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes

  TUCSON, Ariz., and STOCKHOLM, Sweden. December 16, 2020 — The Critical Path Institute (C-Path) and Diamyd Medical (DMYD B; Nasdaq First North Growth Market) are proud to announce their collaboration to significantly improve the scientific community’s insight into type 1 diabetes (T1D) through Diamyd Medical’s contribution of fully anonymized data from a European Phase III trial to the Trial Outcome Markers Initiative (TOMI) T1D integrated database. The Phase III trial evaluated the use of the diabetes vaccine Diamyd^®, an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells. The Data Contribution Agreement (DCA) between Diamyd Medical and C-Path will allow for this unique set of fully anonymized clinical trial data to be integrated into an ever-growing list of committed trial data sets within the TOMI-T1D project.